The Role of Traditional Risk Factors and Inflammation Activity in Atherosclerosis Development in Psoriatic Arthritis Patients
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
It is known that patients with autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus) have early atherosclerosis development which might lead to the life threatening complications and death. Epidemiology studies demonstrated the risk of myocardial infarction, cardiovascular death is increased in patients with psoriatic arthritis (PsA), which also can be explained by premature atherosclerosis development but its risk factors (RF) remain unclear.
The objective: defining relationship of traditional RF for cardiovascular diseases (CVD) with the activity of the inflammatory process and atherosclerosis in patients with PsA.
Materials and methods. The study included 42 patients with PsA and 20 patients with skin psoriasis (PS) who did not have atherosclerotic CVD, diabetes, chronic kidney disease and other serious diseases and did not take statins. The control group consisted of 20 healthy persons who had no signs of rheumatic, infectious and other inflammatory diseases. All enrolled patients underwent complete physical examinations, evaluation of disease activity (DAS28, PASI indexes); laboratory investigations included full blood count and ESR, CRP, plasma lipids and uric acid level. Ultrasound of carotid arteries was performed to evaluate the surrogate atherosclerosis markers – intima-media complex thickness (IMT) and atherosclerotic plaques (AP).
Results. It was determined that in patients with PsA, the severity of the atherosclerotic process is more prominent compared to patients with PS (the traditional RF profiles were the same).
Сonclusion. The highest level of C-reactive protein, fibrinogen, uric acid, thicker intima-media complex was found in PsA group, which may indicate a pathogenetic association of additional RF with the development of a more aggressive atherosclerotic process.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Badokin V.V. Terapevticheskaya aktivnost’ i bezopasnost’ artrofoona pri psoriaticheskom artrite / V.V. Badokin, Yu.L. Korsakova // Consilium Medicum [E’lektronny’j resurs]. – 2006. – № 8. – Rezhim dostupa: http://con-med.ru/magazines/ consilium_medicum/212569/212305/. – Data dostupa: 27.03.2014.
Cytokine profiles during infliximab monotherapy in psoriatic arthritis / A. Mastroianni [at al.] // British Journal of Dermatology. – 2005. – Vol. 153, № 3. – P. 531–536.
Gottlieb A.B. Psoriasis comorbidities / A.B. Gottlieb, C. Chao, F. Dann // Journal of Dermatological Treatment. – 2008. – Vol. 19, № 1. – Р. 5–21.
Milosavljevic, J. Ultrasound and Power Doppler Evaluation of the Hand and Wrist in Patients with Psoriatic Arthritis / J. Milosavljevic, U. Lindqvist, A. Elvin // Acta Radiologica. – 2005. – Vol. 46, № 4. – P. 374–385.
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics / A. Gottlieb [at al.] // Journal of the American Academy of Dermatology. – 2008. – Vol. 58, № 5. – P. 851– 864.
Effects of alefacept on health-related quality of life in patients with psoriasis results from a randomized, placebo-controlled phase II trial / C.N. Ellis [at al.] // American Journal of Clinical Dermatology. – 2003. – Vol. 4, № 2. – P. 131–139.
Stefano I. Echographic test and cyclosporine therapy in psoriatic arthritis / I. Stefano, R. Eugenio, R. Antonio // Journal of the European Academy of Dermatology and Venereology. – 2000. – Vol. 14, № 3. – P. 232–233.
Kochergin N.G. Itogi raboty’ Pervoj vsemirnoj konferencii po psoriazu i psoriaticheskomu artritu / N.G. Kochergin, S.N. Kochergin, L.M. Smirnova // Russkij medicinskij zhurnal [E’lektronny’j resurs]. – 2006. – Rezhim dostupa: http://www.rmj.ru/articles_4306.htm. – Data dostupa: 03.04.2014.
Psoriasis and diabetes: a population-based cross-sectional study / A.D. Cohen [at al.] // Journal of the European Academy of Dermatology and Venereology. – 2008. – Vol. 22, № 5. – Р. 585–589.
Titov V.N. Vzaimosvyaz mochevoy kisloty s pokazatelyamya lipidnogo obmena u lits s nizkim i srednim riskom po shkale SCORE / V.N. Titov, S.A. Boytsov, S.F. Urazalina i soavt. // Ateroskleroz i dislipidemii. – 2013. – № 2. – S. 31–39.
Chandran V. Sensitivity and specificity of the caspar criteria for psoriatic arthritis in a family medicine clinic setting / V. Chandran, C.T. Schentag, D.D. Gladman // The Journal of Rheumatology. – 2008. – Vol. 35, № 10. – P. 2069–2070.
Mіtchenko O.І., Lutay M.І. Dislіpіdemії: dіagnostika. profіlaktika ta lіkuvannya. Metodichnі rekomendatsії asotsіatsії kardіologіv Ukraїni. – K.: Morіon. 2011.
Kovalenko V.M Vpliv іmunnogo statusu і lіpіdnikh faktorіv na progresuvannya subklіnіchnogo aterosklerozu і rozvitok sertsevo-sudinnikh zakhvoryuvan u patsієntіv іz revmatoїdnim artritom // V.M. Kovalenko, L.V. Khimion, G.І. Lysenko, O.O. Garmisch / Ukr. tevmatol. Zhurn. – 2011.
Gonzalez-Juanatey C., Llorca J., Amigo-Diaz E. [et al.] High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. // Arthritis Rheum. – 2007. – 57 (6). – Р. 1074–1080.
Franse LV. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP) / Franse LV, Pahor M, Di Bari M et al. // J. Hypertens. – 2000. – Vol. 18. – P. 1149–1154.
Grayson PC. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. / Grayson PC, Kim SY, LaValley M et al. // Arthritis Care Res (Hoboken). – 2011. – Vol. 63 (1). – Р. 102–110.
Keenan T. Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. / Keenan T, Blaha MJ, Nasir K et al. // Am J Cardiol. – 2012. – Vol. 110 (12). – P. 1787–1792.
